SCHEMBL3865601

SCHEMBL3865601

COc1ccc(-n2nc(C(=O)CCCO[Si](C)(C)C(C)(C)C)cc2-c2cc(C)cs2)cc1

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 6/20 0.47
PTGS1 P23219 1/20 0.47
CHRNA7 P36544 1/20 0.40
RPA1 P27694 2/20 0.40
FABP3 P05413 1/20 0.37
FABP4 P15090 1/20 0.37
MALT1 Q9UDY8 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
CNR1 P21554 1/20 0.36
CNR2 P34972 1/20 0.36
CFTR P13569 1/20 0.35
MARS1 P56192 1/20 0.35
CCKAR P32238 3/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
RXRG P48443 1/20 0.34
MGLL Q99685 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3866166 0.93 PTGS2 (0.38) PTGS2PTGS1CHRNA7RPA1FABP4
SCHEMBL3871118 0.90 SMPD1 (0.39) PTGS2PTGS1CHRNA7FABP3FABP4
SCHEMBL3864475 0.90 CHRNA7 (0.41) PTGS2PTGS1CHRNA7RPA1MALT1
SCHEMBL3876646 0.90 CHRNA7 (0.38) PTGS2PTGS1CHRNA7FABP3FABP4
SCHEMBL5150756 0.90 PTGS2 (0.41) PTGS2PTGS1RPA1FABP3FABP4
SCHEMBL3865539 0.89 CHRNA7 (0.41) PTGS2PTGS1CHRNA7FABP3CA1
SCHEMBL3865595 0.80 PTGS2 (0.56) PTGS2PTGS1CHRNA7RPA1FABP3
SCHEMBL3863718 0.77 RPA1 (0.50) PTGS2CHRNA7RPA1MALT1CA1
SCHEMBL3867347 0.77 FABP3 (0.34) FABP3FABP4
SCHEMBL3866161 0.74 PTGS2 (0.45) PTGS2PTGS1CHRNA7RPA1FABP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2009-01-01 US disclosed
US-7442802-B2 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2008-10-28 US disclosed
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-31 US disclosed
US-7087630-B2 Cyclooxygenase 2 selective inhibitors, compositions and methods of use NITROMED, INC. (US) 2006-08-08 US disclosed
EP-1534683-A4 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED INC (US) 2005-08-24 EP disclosed
EP-1534683-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE Nitromed, Inc. (US) 2005-06-01 EP disclosed
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use NITROMED, INC. 2004-03-18 US disclosed
WO-2004002409-A2 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE NITROMED, INC. (US) 2004-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053985-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885
US-20060194861-A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885
US-20090005350-A1 CYCLOOXYGENASE-2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE PTGS2, PTGIS, PTGES2 PTGS2 1/4885PTGS1 4/4885CHRNA7 4626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.